CASI Pharmaceuticals (CASIF) Current Leases (2021 - 2024)

CASI Pharmaceuticals has reported Current Leases for 4 years, with the latest figure at $1.2 million in Q4 2024.

• For the quarter ending Q4 2024, Current Leases rose 67.72% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2024 stood at $1.2 million (up 67.72% YoY), and the FY2024 full-year result was $1.2 million, up 67.72% from the prior year.
• Current Leases for Q4 2024 stood at $1.2 million, up from $728000.0 in the prior quarter.
• The five-year high for Current Leases was $1.2 million in Q4 2024, with the low at $728000.0 in Q4 2023.
• Historically, Current Leases has averaged $969500.0 across 4 years, with a median of $964500.0 in 2021.
• Annual changes were most pronounced in 2022 — Current Leases retreated 18.19% — and 2024, when it jumped 67.72%.
• CASI Pharmaceuticals' Current Leases stood at $1.1 million in 2021, then dropped by 18.19% to $868000.0 in 2022, then dropped by 16.13% to $728000.0 in 2023, then jumped by 67.72% to $1.2 million in 2024.
• The last three Current Leases figures came in at $1.2 million (Q4 2024), $728000.0 (Q4 2023), and $868000.0 (Q4 2022), per Business Quant data.